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1.0 INTRODUCTION 
_________________________________________________________________________________ 
Key Points 
1. There is a large body of evidence regarding body composition and interventions with 
physical exercise and nutrition in early stage (I – III) breast cancer 
2. Very little is known about the effects of physical exercise and nutrition on body composition 
in the metastatic breast cancer (stage IV) population 
3. The evidence suggests that body composition is an important prognostic factor in both early 
stage and metastatic breast cancer 
 
Breast cancer is the most prevalent cancer among women, and due to advances in 
screening and treatment of cancer, women are now living longer with the disease. Hence, 
there is a significant population of women worldwide with breast cancer, as well as 
survivors. It is estimated that one in eight Australian women will develop breast cancer in 
her lifetime [1].  As a result, health practitioners are more likely to encounter these women 
on a regular basis. This is also true for women with the incurable form of the disease, 
metastatic breast cancer. Metastatic breast cancer, classified as stage IV cancer, is the 
uncontrollable growth of new tissue that starts in a mammary gland and then spreads to  
other parts of the body [2].  
Breast cancer itself, as well as the treatments, can have debilitating effects on the 
individual and severely reduce quality of life. Some common symptoms include nausea, 
fatigue, constipation, lack of appetite and nerve pain [3]. Moreover, women diagnosed with 
breast cancer are prone to psychosocial distress and experience issues with depression, 
decreased self-esteem and body image [4]. 
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  Because of the increased prevalence and survival rates, breast cancer research 
continues to gain momentum and there is a growing body of research into various aspects 
of breast cancer treatment and symptom management. It has been discovered that body 
composition, especially at diagnosis of breast cancer, significantly impacts the effectiveness 
of treatment and its success in the early stages, I - III [5]. Therefore, women who are 
overweight or obese i.e. body composition comprises greater fat versus muscle mass, are at 
higher risk for poor prognosis, reducing prospects for survival. Body composition has a 
direct impact on decreased time to tumour progression [6] and overall mortality in breast 
cancer patients [7]. In contrast however, only a few studies around this topic have been 
conducted in metastatic breast cancer. The treatment for metastatic breast cancer is 
different to early stage breast cancer, as it would be primarily palliative. There is little 
known about the impact of this form of the disease on body composition and if these 
women would derive benefits from interventions with physical exercise and nutrition. 
This paper investigates metastatic breast cancer from aetiology and risk factors to 
the impact on the individual, and reviews the evidence surrounding these issues and their 
management. It will summarise the clinical trials that have been conducted and the results 
that can be used to inform practice or provide guidance for this population. It is hoped that 
this work will bring light to best practice, indicate gaps in the evidence and give direction 
regarding future research in the area.  
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2.0 LITERATURE REVIEW 
 
 There is still no definitive aetiology for breast cancer, as it can develop when the 
genetic information the individual’s cells carry changes or mutates [8]. How these changes 
come about and how the cells then develop, depends on many factors in the environment 
and in the individual and how they impact each other. Some risk factors are modifiable and 
can be addressed by behaviour change, e.g., physical activity, diet and alcohol consumption. 
However, some risk factors, e.g., gene mutations, are unavoidable [9].  
 One of the highest risk factors for breast cancer is family history of the disease [8]. 
There has been extensive research using breast cancer family data of the BRCA1 and BRCA2 
genes. Mutations in these genes confer  10- to 20-fold relative risks to carriers, 
corresponding to a 30%–60% risk by the age of 60 years [8]. The evidence suggests lifetime 
risk ratios of 1.8 in families with one affected first-degree relative (i.e., mother, sister, 
daughter) and it increases approximately two-fold when two first degree relatives are 
affected [10]. Risk ratios are greatest the younger the age of diagnosis of the first-degree 
relative. 
Specific lifestyle factors, such as exercise and nutritional habits, especially resulting 
in poor body composition, are associated with an increased risk of developing breast cancer. 
There is a growing body of epidemiological evidence surrounding post-menopausal obesity 
and a sedentary lifestyle as important risk factors for breast cancer [11]. Women with lower 
fat mass or who partake in regular exercise have significantly lower insulin, glucose, and 
triglyceride levels and higher high-density lipoprotein cholesterol levels. Thus, weight 
control and physical activity could exert a protective effect against breast cancer through a 
metabolic pathway [12].  
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Epidemiological studies have provided clear associations between dietary patterns 
and breast cancer incidence. A review conducted by Grosso et al (2017) reported an 
association between high adherence to a healthy dietary pattern and decreased risk of 
breast cancer. Healthy dietary patterns in this study were consistent with general dietary 
guidelines, i.e., rich in whole foods (fruit, vegetables, legumes); reduced red meats and 
processed foods; alcohol consumption equivalent to one serving of wine or beer per day. In 
contrast, unhealthy dietary patterns were associated with higher body mass index which 
further increased breast cancer risks.  
Furthermore, any alcohol consumption, is associated with increased risk of 
developing breast cancer [9]. A prospective observational study of 105,986 women enrolled 
in the Nurses' Health Study, followed up from 1980 until 2008, found that consumption of 
three to six alcoholic drinks per week was significantly associated with increased breast 
cancer risk. Cumulative alcohol intake throughout adult life, i.e., consumption both earlier 
and later in adult life, was independently associated with breast cancer risk [13].   
Likewise, exposure to tobacco smoke has been established to provide increased risk 
of breast cancer for both active and passive smokers. Luo et al (2011) found that active and 
passive smoking pathologically confirmed invasive breast cancer. The cohort study reported 
that breast cancer risk increased by 9% between former smokers and non-smokers [14]. 
Current smokers had an even greater risk at 16% compared to non-smokers. Several cohort 
studies have identified risk factors involving specific habits of cigarette smoking, which 
include the duration of smoking, the number of cigarettes smoked, age at initiation, and 
years of cessation [15]. Xue et al (2011) found breast cancer incidence to be elevated in 
ever-smokers versus never smokers and the study reported comparable hazard ratios (HR) 
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between past and current smokers (HR 1.09 versus 1.06, [95% CI], 1.01% - 1.10%), 
suggesting that cessation had little effect following long-term smoking [16]. 
Over time, it has been discovered that obesity, defined as abnormal or excessive fat 
accumulation that presents a risk to health [17], is related to poorer outcomes for women 
diagnosed with metastatic breast cancer [18]. Obesity at the time of diagnosis is associated 
with poor prognosis and reduces the rate of survival and the efficacy of the treatment. In 
2005, a population-based sample of 1,360 Australian women with breast cancer, found that 
obesity was associated with distant recurrence of breast cancer, increased mortality from 
any cause and associated with increased tumour size, and poorer treatment outcomes [19]. 
Additionally, the literature suggests that breast cancer survivors are at increased risk of 
obesity and the metabolic syndrome (MetS) and are at a significantly higher risk of 
developing other chronic diseases such as coronary heart disease [20, 21].  The MetS is 
characterised by the presence of high serum glucose and triglycerides, low HDL-cholesterol, 
high blood pressure, and abdominal obesity. Post-menopausal women with MetS are at 
significantly higher risk (rate ratio 1.58) for breast cancer [22]. Women with low serum HDL-
cholesterol and high triglycerides had the strongest association with breast cancer risk.  
Peri and postmenopausal women are commonly provided Hormone Therapy (HT) for 
control of menopausal symptoms [23]. However, the results from the Women's Health 
Initiative randomised controlled trial comprising over 16,600 women indicated that overall 
health risks exceeded benefits from the use of HT (combined estrogen plus progestin) over 
five years [24]. This trial confirmed that HT does increase the risk of incident breast cancer 
by 53% after use for more than five years. Breast cancer risk also increases based on the 
length of time of exposure to endogenous estrogen hormones, i.e., early menarche and 
women who experience menopause after age 55. 
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Diagnosis 
 Persons with breast cancer may not be aware of having the disease as they may not 
present with any symptoms, especially in the early stages of the disease.  Consequently, the 
World Health Organisation (WHO) position paper on mammography screening promotes 
two early detection strategies for breast cancer; early diagnosis and screening [25]. Early 
detection is critical to improving breast cancer outcomes and survival. Diagnosis is done via 
a three-part process; 1. Taking a personal history and a clinical breast examination; 2. 
Imaging tests (mammogram and/or ultrasound) and 3. A biopsy to remove cells or tissue for 
examination. In a retrospective study of a population of 2070 women affected by invasive 
breast cancer, Cedolini et al (2014) found breast cancer screening resulted in significantly 
higher overall 5-year survival, versus women who had their breast cancer diagnosed by 
objective physical examination or imaging[26]. Women who had their cancers diagnosed by 
objective physical examination had a significantly higher prevalence of advanced stage at 
diagnosis. The result being, significantly higher prevalence of tumour characteristics 
commonly related to poorer breast cancer prognosis such as greater tumour size and 
greater lymph node or lymphovascular involvement. Conversely, the patients who were 
diagnosed via breast cancer screening had a significantly lower prevalence of locoregional 
and distant recurrences. 
 
Types and Staging of Breast Cancer 
 Breast cancers are categorised based on their type and staging. Figure I details the 
eight distinct types of breast cancer. Breast cancers are categorised based on their location 
in the breast, whether the tumour is invasive or non-invasive, and whether it has spread 
(metastasized) to the lymph nodes or other parts of the body [26]. 
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Figure 1 – Types of Breast Cancer1 
Location Description 
Ductal carcinoma (DCIS) non-invasive breast cancer that is confined to the 
ducts of the breast 
Lobular carcinoma (LCIS) a non-invasive breast cancer that is confined to the 
lobules of the breast 
Early breast cancer invasive breast cancer that is contained in the breast 
and may or may not have spread to lymph nodes in the 
breast or armpit.  
Paget’s disease of the nipple a rare form of breast cancer that affects the nipple and 
the area around the nipple (the areola), and is 
commonly associated with an invasive cancer 
elsewhere in the breast 
Inflammatory breast cancer a rare form of invasive breast cancer that affects the 
lymphatic vessels in the skin of the breast, causing the 
breast to become red and inflamed 
Locally advanced breast 
cancer 
an invasive breast cancer that has spread to areas near 
the breast, such as the chest wall 
Metastatic breast cancer / 
advanced breast cancer 
invasive breast cancer that has spread from the breast 
to other parts of the body 
 
Breast cancer is staged according to the American Joint Committee on Cancer (AJCC) 
TNM system, which is based on three factors: 1. The size or diameter of the breast tumor (T) 
and it if has grown into nearby areas; 2. If the cancer has spread to nearby lymph nodes (N) 
and 3. Whether it exhibits invasive characteristics i.e., the cancer has metastasized or 
spread to other parts of the body (M) [27]. Appendix 1 lists the types of tests that are 
commonly used in diagnosis and staging of the disease. The earliest stage cancers are called 
stage 0 and then range from stages I to IV. The lower the number indicates the less the 
cancer has spread. Appendix 2 describes the stages of cancer.  
 
                                                          
1
 Australian Government. Types of breast cancer | Breast cancer. 2015 2015-12-18T09:00+11:00 [cited 2017 
November 17]; Available from: https://breast-cancer.canceraustralia.gov.au/types. 
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Types of Treatment 
 Anti-cancer treatment may be for curative or palliative intent depending on the type 
and staging of the disease. Adjuvant therapy has a curative intent and is customarily used 
following primary radical treatment to reduce the risk of cancer recurrence. Adjuvant 
therapies are well-established forms of treatment for common malignancies such as breast 
cancer. These include hormone therapies, chemotherapy (systemic therapy targeting micro-
metastases) and radiation therapy (local tumour control) and can be given individually or 
combined [28]. Neo-adjuvant therapy refers to therapy given before the primary treatment 
and it is also applied as part of curative treatment. It may be used to reduce large tumors, 
which may aid in surgery. It may be important for some patients to avoid the treatment 
delay caused by surgery and recovery and as such neo-adjuvant therapy is utilised to treat 
both the primary tumour and potential micro-metastases [28]. The appropriate treatment 
protocol must be ascertained for each patient, as metastatic breast cancer has 
unpredictable clinical behaviour and is subject to biological heterogeneity [29].  
Palliative care is offered to patients with metastatic cancers. The WHO definition of 
palliative care is, “an approach that improves the quality of life of patients and their families 
facing the problem associated with life-threatening illness, through the prevention and 
relief of suffering by means of early identification and impeccable assessment and 
treatment of pain and other problems, physical, psychosocial and spiritual” [30]. Palliative 
care is therefore multi-modal, and early initiation has been found to have beneficial effects 
for both patients, their families and the healthcare system [31]. The literature suggests 
improvement in symptoms such as depression, reduced aggressive care at the end of life, 
increased advanced directives, improved patient and caregiver quality of life, reduced 
hospital length of stay and hospitalizations, and reduction in the medical cost of care [31]. 
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Cancer-related Malnutrition  
The nutritional status of patients with cancer has a significant impact on their 
treatment outcome. The aetiology of malnutrition in patients with cancer is multifactorial 
[32] and can result from the systemic effects and/or the local effects of the tumor, or the 
side effects of anti-cancer treatment [33]. Cancer-related malnutrition occurs because of an 
imbalance between the increased nutritional needs of the patient, the demands of the 
tumor and the availability of nutrients in the body [32]. Additionally, malnutrition can 
present in both overweight and underweight individuals. Cancer cachexia, a specific form of 
malnutrition, can result from prolonged undernutrition and is characterised by systemic 
inflammation, progressive, involuntary weight loss with depletion of lean body mass, muscle 
wasting and weakness, oedema, impaired immune responses, and declines in motor and 
mental function [32, 34]. Cachexia also significantly increases the risk of death and is one of 
the primary causes of death in cancer [35]. Notably, patients with metastatic disease are at 
significantly increased risk of malnutrition [33, 36]. Hebuterne et al (2014) found the 
prevalence of malnutrition in women with breast cancer to be approximately 20 percent 
and even greater likelihood in metastatic breast cancer with an odds ratio of 2.97 (95% CI: 
2.14-4.12).  
It is established that risk of sarcopenia increases in breast cancer patients 
undergoing chemotherapy or androgen therapy [37]. Sarcopenia is a syndrome 
characterised by progressive and generalised loss of skeletal muscle mass and strength with 
a risk of adverse outcomes such as physical disability, poor quality of life and death [38]. 
There is now increasing evidence that weight gain in breast cancer patients consists almost 
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entirely of increased adipose tissue with no gain, or even loss, of lean tissue. This 
mechanism is called ‘sarcopenic’ obesity [39]. Consequently, there is reduced muscular 
strength and increased muscular dysfunction. The literature indicates that muscle wasting is 
frequently observed in normal, overweight or even obese cancer patients [40]. As such, a 
decrease in skeletal muscle mass can often be masked by excess fat mass. Sarcopenia, 
which encompasses a low amount of muscle mass and relatively high amount of fat mass, is 
a major physical issue that presents in women with metastatic breast cancer [5, 41, 42].  
This can be due to the disease, the age of the individual at diagnosis and because of 
treatment, for instance, hormonal treatment impacting on fat metabolism and resulting in 
fat deposition [43].  
It therefore stands to reason that poor body composition metrics are inversely 
related to treatment tolerance. Shachar et al (2017) found that patients with low skeletal 
muscle index and low lean body mass developed grade 3/4 toxicity (relative risk 1.29 and 
1.48; P=0.02, respectively), which was significantly higher than toxicity levels experienced by 
those with a greater skeletal muscle index [44]. Increased incidence and severity of 
treatment-related toxicity have also been exhibited in malnourished patients compared 
with those patients with normal, stable weight [45]. It was determined that the occurrence 
of muscle wasting is a significant predictor of toxicity and time to tumour progression (TTP) 
in metastatic breast cancer patients treated with chemotherapy. Toxicity was found in fifty 
percent of the sarcopenic patients in this study versus twenty percent in the non-sarcopenic 
patients [45]. Therefore, it is imperative that the individual with breast cancer limit the loss 
of muscle mass after diagnosis [46].  
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There has been extensive research regarding physical exercise interventions to 
maintain muscle mass, fitness and quality of life during cancer treatment for patients with 
early-stage cancers [47]. Physical exercise is an effective intervention to improve 
cardiorespiratory fitness, physical functioning and overall quality of life in breast cancer 
patients and survivors [48]. Individuals with higher muscle mass have greater ability to 
tolerate chemotherapy and have better survival rates [49]. Ballard-Barbash et al (2012) 
reported in their systematic review that there was consistent evidence that high levels of 
daily physical activity are associated with reduced all-cause, breast cancer-specific mortality. 
Overall, the current literature indicates that supervised exercise therapy, in both aerobic 
and resistance training, was found to be safe, feasible and positively associated with 
decreased fatigue and improved fitness, in patients with early-stage breast cancer receiving 
conventional cytotoxic adjuvant therapy versus usual care [50].  Resistance exercise has 
been shown to be effective in maintaining muscle mass and aerobic training effective in 
reducing fat mass, in patients with early-stage breast cancer [51].  
 
Nutrition 
Individualized nutritional support is an essential part of the multi-modal approach 
for the care of cancer patients [52]. It has been established that cancer cachexia is a 
progressive wasting disease that cannot be fully reversed by conventional nutrition support 
[53]. Therefore, early initiation of nutrition intervention is highly recommended. As 
previously discussed, muscle wastage and weight loss are critical issues for cancer patients. 
Early recognition and treatment of the nutritional and metabolic alterations occurring 
during cancer are critical [38]. As such, adequate nutritional support should be provided to 
minimize sarcopenia or wasting [52].  
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Research has indicated the advantages of various nutritional interventions in 
maintaining appropriate nutritional status and body composition during breast cancer 
treatment. In this regard, the ESPEN guidelines on nutrition in cancer patients recommends 
consumption of 1-1.5 g/kg protein per day, as the increased protein intake promotes muscle 
protein anabolism [54]. Likewise, omega-3 polyunsaturated fatty acids, in doses of at least 
1.5 g/day of EPA for a prolonged time to advanced cancer patients experiencing weight loss, 
has been found to be useful in the modulation of metabolic changes and associated with 
improvement of clinical, biological and functional parameters and may help reduce muscle 
wasting [55]. Several research groups have conducted studies surrounding the efficacy of 
docosahexaenoic acid (DHA) which is an omega-3 polyunsaturated fatty acid of marine algal 
origin and provided by the diet. The results suggest that DHA can increase the efficacy of 
anti-cancer treatments by increasing tumour sensitivity to chemotherapy, while not 
affecting non-tumour tissues [56]. Consequently, this is particularly beneficial for patients 
with metastatic disease. 
Conclusion 
Physical activity and nutrition are essential factors during breast cancer survivorship 
which impacts on body composition, cancer recurrence, and quality of life. The growing 
body of evidence surrounding the effectiveness of physical exercise and nutrition for 
maintaining appropriate body composition in non-metastatic cancer patients is compelling. 
Despite this, very little research has been conducted on the effects of physical exercise 
combined with nutrition interventions in women with metastatic breast cancer.  
It is evident that more women are living longer post diagnosis of metastatic breast 
cancer. Therefore, this systematic review was conducted to investigate the impact of 
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interventions with physical exercise and nutrition on body composition in women with 
metastatic breast cancer. The results are discussed in the next chapter.  
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ABSTRACT 
Purpose 
Breast cancer is one of the most common types of cancer in women. In metastatic 
breast cancer, quality of life is essential and directly associated with body composition. This 
review aims to evaluate the evidence for physical exercise intervention and/or nutrition 
intervention on body composition in women with metastatic breast cancer. Secondary 
outcomes of interest are fatigue, quality of life, survival, toxicity, and depression. 
 
Methods 
 Pubmed, CINAHL, Cochrane Central and EMBASE databases were searched from 
database inception to October 25th, 2017, using key words and controlled vocabulary. All 
studies that investigated the effect of physical exercise and nutrition interventions in adult 
women with metastatic breast cancer were included. 
 
Results  
No studies were identified that investigated the effects of exercise and / or nutrition 
interventions on body composition in this population. Seven studies reported positive 
results of physical exercise interventions on the secondary outcomes of fatigue, quality of 
life and survival. These studies had low statistical power as they had small sample sizes. 
 
Conclusions  
There is insufficient evidence to draw a positive conclusion regarding the impact of 
physical exercise or nutrition in women with metastatic breast cancer. There is a cautious 
indication that physical exercise at least does no harm to patients with metastatic breast 
cancer. Further trials with robust study designs are needed. 
 
Key words 
Metastatic breast cancer, physical exercise, nutrition, body composition, fatigue, quality of 
life 
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INTRODUCTION 
Although breast cancer is the most common cancer among women in the world 
(25% of all cancers), it has a high survival rate when detected and treated early [57, 58]. 
Survival rates continue to improve due to advances in cancer prevention, diagnosis, and 
treatment [59]. In Australia, the overall five-year survival rate for breast cancer in females is 
90% and if the cancer is limited to the breast, the five-year survival rate increases to 96% 
[1]. Early detection, which involves screening and early diagnosis, is crucial to ensure that 
appropriate treatment is commenced promptly. 
Despite treatment advances, there is a growing number of women who develop 
metastatic breast cancer, where the cancer spreads beyond the primary site of the breast to 
other parts of the body. This is also called ‘advanced’ or ‘stage IV’ breast cancer [26]. 
Metastatic breast cancer is virtually incurable and is the cause of death for women who die 
from breast cancer. In developed countries like Australia, approximately 20 to 30% of 
women with breast cancer are likely to be diagnosed with stage IV breast cancer [60], where 
treatment options are primarily palliative, or not for curative intent [61].  Although the five-
year survival rate for this population of women is presently 40%, it has been increasing over 
time and indicates that more women are living longer with metastatic breast cancer.  
Inherent with a diagnosis of breast cancer are adverse side effects. Common 
symptoms that accompany breast cancer treatment include psychosocial distress, typically 
anxiety and depression [62, 63].  About one-third of women are severely impacted and 
these symptoms can persist for years [64]. Additionally, cancer-related fatigue is 
experienced by 80 – 100% of women with breast cancer during chemotherapy [65]. Another 
important symptom of breast cancer treatment is involuntary weight gain. Recent studies 
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have reported that the prevalence is approximately 35 -85% of patients with breast cancer 
[66, 67]. Women with breast cancer undergoing chemotherapy or androgen therapy are 
also at an increased risk of sarcopenia [37], i.e. a syndrome characterised by progressive and 
generalised loss of skeletal muscle mass and strength [38]. Consequently, these symptoms 
can have debilitating effects on physical functioning and quality of life.   
It has been discovered that in early-stage breast cancer, body composition is a 
determinant of improved prognosis for the patient [49]. Individuals with cancer that have a 
relatively high muscle mass have a greater ability to tolerate chemotherapy and have better 
survival rates than individuals with a relatively low muscle mass [49]. There is a large body 
of evidence regarding the effects of physical exercise and nutrition intervention on body 
composition and hence weight management, sarcopenia and other common symptoms, in 
women with early stage (I – III) breast cancer. Resistance exercise has been indicated to help 
reverse the effects of sarcopenia during adjuvant chemotherapy [5]. Physical exercise is an 
effective intervention to improve body composition, cardiorespiratory fitness, physical 
functioning, fatigue and overall quality of life in early breast cancer patients and survivors 
[48]. Ballard-Barbash et al (2012) reported in their systematic review that there was 
consistent evidence that physical activity is associated with reduced all-cause and breast 
cancer-specific mortality [68].  
In addition to physical exercise, nutrition is a key component in ensuring appropriate 
body composition is maintained. There is evidence that dietary protein in conjunction with 
physical exercise, enhances muscle growth and prevents muscle loss in patients with age-
related sarcopenia [69]. However, in cancer patients, standard interventions are not 
sufficient to reverse the impact of the systemic, metabolic syndrome of muscle loss and 
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wasting due to the disease [70, 71]. Due to these metabolic alterations resulting in physical 
inactivity, low dietary intake and potential anabolic resistance, the situation in cancer care is 
even more challenging. It is compounded by the fact that the feasibility and effect of 
physical exercise and nutrition interventions have not been sufficiently investigated in 
metastatic breast cancer yet.  
 
Objective 
This systematic review aims to evaluate the evidence for physical exercise 
intervention and/or nutritional intervention on the primary outcome of body composition in 
adult women with metastatic breast cancer receiving any treatment, versus no treatment. 
Secondary outcomes of interest are fatigue, quality of life, survival, toxicity, and depression.  
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METHODS 
 
The study was registered in the PROSPERO database and reported in accordance 
with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines [72].  
 
Search Terms 
Electronic searches were conducted in the Pubmed, CINAHL, Cochrane Central and 
EMBASE databases up to October 25, 2017.  Database searches included predefined key 
terms and no automatic filters were used. The studies that were identified from the 
databases were saved and managed in Covidence [73], a platform created by Cochrane for 
systematic reviews. Numbers were recorded and reported in a PRISMA flowchart (Figure 1).  
Appendix 3 describes the complete search terms which included:  
Stage IV OR metastatic OR “Stage four” AND 
Breast OR Mammalia* AND  
Malignan* OR Neoplas* OR Tumour* OR cancer* OR carcinoma* AND 
Protein OR “amino acid” AND  
Supplement* OR nutrition* OR diet* OR "Fatty Acids, Omega-3+" OR “Fish Oils” OR "n-3 
polyunsaturated" OR “Eicosapentaenoic Acid*” OR “Docosahexaenoic acid*” OR 
“Physical activity” OR Exercise OR “resistance training” OR cardiovascular OR exercise OR Yoga OR 
Pilates OR hydrotherapy OR aerobic* OR "Therapeutic Exercise" 
25 
 
Eligibility criteria 
This review initially aimed to include only RCTs, but after the initial and full-text 
screening revealed only two RCTs on this topic it was subsequently expanded to include all 
prospective studies that measured the effects of physical exercise and/or nutrition 
interventions versus a control, usual care or no intervention. The primary outcome was 
body composition, however, studies that did not report body composition were eligible if 
reporting any of the secondary outcomes of interest, which were fatigue, quality of life, 
survival, toxicity or depression.  
The population being investigated was adult women 18 years and over who were 
diagnosed with stage IV or metastatic breast cancer, undergoing any kind of treatment 
including chemo and / or radiation therapy, hormone therapy and palliative care or no 
treatment. Studies with any physical activity and / or nutrition intervention with a minimum 
duration of 4 weeks were included. Studies were only eligible if written in the English 
language. 
 
Exclusion criteria 
Studies that did not report comprehensive results (e.g. study protocols or conference 
abstracts) were excluded, and studies that did not have any full text online or library access 
were excluded. 
 
Data Management  
The studies located from the electronic database searches were imported into the 
Covidence platform [73]. Two independent reviewers (CI and AB) conducted initial screening 
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for relevance, based on the titles and abstracts. Conflicts were resolved by the third 
reviewer (BM). When necessary, full text papers were used to determine if the study met 
the criteria. Where full text publications/papers were not available, the authors were 
contacted via email requesting access to the results or the full text paper.  
  
Assessment of Risk of Bias in included studies  
1. The risk of bias of the included studies was assessed by using The Downs and Black 
evaluation tool [74] by CI as the first assessor and AB and BM as second assessors. 
Conflicts were resolved by BM, where applicable. The Downs and Black evaluation 
tool is validated to judge the quality of both randomized and non-randomized study 
designs. Each study was assigned a grade of low, medium or high risk of bias, based 
on each of the following parameters; 1. Reporting bias, 2. External validity, 3. 
Internal validity, 4. Selection bias 5. Power.  
 
RESULTS 
 The electronic database searches identified 3420 potentially relevant studies 
summarised in Figure 1. After removal of duplicates and initial screening sixty-two studies 
were discovered for full text screening. However, only abstracts could be located for six of 
the studies. Following several failed attempts to contact the authors, five studies were 
excluded due to inability to determine relevance to the review and one study is ongoing, 
hence no results were available. After full-text screening, seven studies conformed to the 
inclusion criteria, featuring two RCTs and one quasi RCT, and were eligible for the review.  
 The final selection of seven studies comprised a total of 348 women with metastatic 
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breast cancer. There was high heterogeneity regarding study designs and outcomes, as all 
had different interventions and outcome parameters. All studies had a form of physical 
activity [75-81] and one study had a physical exercise and nutrition component [75]. Two 
studies investigated the effects of yoga on fatigue [77, 80]. One study intervened with gentle 
seated exercise, another used moderate intensity exercise and one study was a case report 
using a combination of various exercises. The Block Centre [75] employed a holistic 
approach to cancer care including strength, endurance and range of motion exercises. Yee et 
al (2014) explored the difference in physical activity levels between women with metastatic 
breast cancer living in the community versus their healthy counterparts.  
None of the studies reported on the primary outcome of body composition. Three 
studies reported on fatigue. However, meta-analysis could not be performed as the studies 
were too diverse in study design and handling of control groups. Additionally, different 
measurement tools and statistical tests were employed; results were not reported in any 
standardized manner, and missing data prevented meaningful meta-analysis. Table 1 
summarises the design of the seven included studies.  
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Figure 1 – PRISMA Flowchart 
PRISMA Flowchart 
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Table 1 – Summary of interventions and outcome measures 
 
Study Intervention 
(duration/frequency) 
Control Outcome measure of interest 
Ligibel, 2016 Moderate intensity exercise  
 
Duration – 16 weeks 
Frequency – 150 minutes/ 
week  
Wait list  Physical functioning – 
EORTC QLQ-C30 
 Fatigue - Functional 
Assessment of Chronic 
Illness Therapy (FACIT)-
Fatigue 
 QoL - EORTC QLQ-C30 
Vadiraja, 
2017 
Yoga 
 
Duration – 3 months  
Frequency – 24 sessions 
Supportive therapy 
and education 
 Fatigue severity and 
Frequency – Fatigue 
Symptom Inventory 
Headley, 2004 Seated exercise 
 
Duration – 4 cycles of 
chemotherapy 
Frequency – x 3/week  
Continued usual 
physical activities 
 Fatigue and QOL – 
Functional Assessment of 
Chronic Illness Therapy–
Fatigue Version IV (FACIT–F) 
Block, 2009 Interval and endurance 
training, strength training   
therapeutic Yoga, Pilates 
and Qi gong 
 
Duration – Ongoing    
None  Survival – months  
Carson, 2007 Yoga 
 
Duration – 8 weeks 
Frequency – Daily  
None  Fatigue – daily diary logs 
 
Yee, 2014 Average steps / day  
Time spent in moderate-to-
vigorous intensity physical 
activity 
 
Duration – 7 days 
Frequency – no intervention 
Healthy women in 
community 
 Fatigue - FACIT-F   
 
Born, 2010 Resistance training, 
mobility, coordination, 
ball/stick skills, 
cardiovascular training 
 
Duration – 9 weeks 
Frequency – once/week  
None  Exercise capacity – 6 min 
walk test 
 QoL – RAND-36 
questionnaire 
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Quality Analysis 
 
Risk of bias  
 Table 2 summarises the Downs and Black domains and the results of how 
each study was assessed. The high heterogeneity of the studies was clear in the assessment 
of risk of bias. The studies used varied designs, some randomized and non-randomized, and 
with or without a control arm, which directly impacts risk of bias. According to the risk of 
bias assessment by the Downs and Black evaluation tool, most of the studies scored 
between 17 – 27 out of a maximum of 32 points. Due to the diversity of the studies, there 
were some parameters within the domains of the tool that were not applicable to all the 
studies. However, most were judged as having a low to medium risk of bias for all 
parameters, except for the Yee et al (2014) and Born et al studies which were judged to have 
a higher risk of bias. Risk of bias was negatively affected when studies relied on patient self-
report or subjective data. Although there were small sample sizes, six of the studies were 
awarded maximum points for power. As it is impossible to blind participants to an exercise 
intervention, studies were not excluded when judged high risk of bias in this domain. 
Instead, each study was judged on its merit according to each parameter.  
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Table 2 – Risk of Bias of included studies as assessed by the Downs and Black Risk of Bias Tool 
 
Summary Table - Risk of Bias 
Author, year 
Reporting 
Bias 
External 
Validity 
Internal 
Validity 
Internal 
Validity 
(selection 
bias) Power Notes 
Ligibel, 2016 Low Low Medium Low Low ·     n = 76 
·     RCT - moderate intensity 
exercise 
·     High attrition rate.  
·     Self-report data collected 
Vadiraja, 2017 Medium Medium Medium Low Low ·     n = 65 
·     RCT - Yoga vs supportive 
counseling intervention 
·     Unable to blind subjects 
  
Headley, 2004 Low Medium Medium Low Low ·     n = 32 
·     Quasi RCT - seated exercise 
intervention 
·     Low self-report data 
collected 
  
Block, 2009 Low Low Medium Medium Low ·     n = 90 
·     Observation study 
·     Integrated care (nutrition, 
exercise, mind-spirit) vs 
usual care  
·     Survival data  
Carson, 2007 Low Low Medium Medium Low ·     n = 13  
·     Feasibility pilot study 
·     Yoga-based program 
·     Small sample size 
Yee, 2014 Low Low Medium High Low ·     n = 71 
·     No intervention  
·     MBC patients vs healthy 
population 
·     No confounders reported 
Born, 2010 Medium High Medium Medium High ·     n = 1 
·     Individual case report 
·     Low power 
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Outcome Measures 
  
Although the included studies involved interventions with physical exercise and / or 
nutrition, none of the studies assessed body composition as an outcome. The included 
studies reported on the secondary outcomes of interest for this review: fatigue, quality of 
life and survival. The most common outcomes for these studies were fatigue (5 studies) and 
quality of life (3 studies). Exercise capacity (2 studies), physical functioning (1 study), survival 
(1 study) and muscle strength (1 study) were the other outcomes of interest. There were 
four tools employed in the studies to measure fatigue and three questionnaires to measure 
quality of life (Table 1). Quality of life (QoL) encompasses various aspects of life and is 
measured over several subjective and objective domains. These instruments are all 
validated tools commonly used in the assessment of QoL in cancer patients. The customary 
domains include functioning (e.g., physical, cognitive, emotional) and symptoms (e.g., 
fatigue, pain, dyspnea). 
 
 Interventions 
 Block et al (2009) is an observational case series that reported on the BCICT whose 
integrated cancer treatment program incorporated physical exercise and a nutrition 
component consisting of personalized nutrition and a supplement regimen. This was the 
only study with a nutrition component, however, there were no results reported on the 
specific effects of the nutrition intervention. The other studies included Yoga, and various 
combinations of aerobic and or resistance exercise interventions, which differed in mode, 
timing and intensity. Table 3 summarises the designs and findings of the studies.  
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Effects of Interventions 
Fatigue 
Of the seven studies, five reported on fatigue as an outcome and of those, three 
investigated a yoga intervention and two employed moderate intensity exercises. The 
Carson et al (2007) study findings suggest that patients who practiced Yoga longer on a 
given day were more likely to experience lower levels of fatigue and that the positive effects 
of Yoga were indicated to continue the day after exercise. Yoga was also used by Vadiraja et 
al (2017) in their exercise arm. They report between group analysis that their intervention 
group experienced better decrease in fatigue severity and frequency compared to the 
control group with over 61% and 64% respective change from baseline between 
comparators. Within group analysis also indicated a significant decrease in fatigue severity 
and frequency.  Similarly, in Headley et al (2004) the intervention group participating in 
seated exercise experienced less increase in fatigue and slower decrease in physical QoL 
compared to a control (usual activities). Fatigue scores saw a reduction from 77% to 56% of 
maximum, over the duration of the intervention [78]. Another study indicated no significant 
difference between the intervention group employing moderate intensity exercise versus 
the wait list control group [79]. However, there was a high attrition rate (23%) in the 
intervention arm versus control. The community-dwelling subjects with metastatic breast 
cancer group indicated higher levels of fatigue (X = 38.0 (9.8) versus their control group 
healthy counterparts (X = 46.3 (4.6) in the Yee et al (2014) study [81]. Overall, the studies 
indicated the positive impact of physical exercise on fatigue. However, due to the low 
sample size, the statistical power of these results is low.
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Table 3 – Summary of Study designs and Findings of the 7 included studies 
 
Study Size and Design 
Data 
 
Findings 
Ligibel, 2016 
n=76 
Randomised control trial 
  Exercise  
(Standard 
Deviation)2 
Control  
(Standard 
Deviation) 
 Nonsignificant improvement in physical functioning 
in intervention vs controls at 16 weeks 
 Participants in intervention group reported non-
significant improvements in global QoL 
 No significant differences noted for fatigue and 
exercise self-efficacy in intervention vs control 
 Moderate intensity physical activity is safe for 
women with metastatic breast cancer (MBC) 
 ~70% of intervention group completed the exercise 
program vs 84% of control group 
  
QoL (EORTC QLQ-30)3 
Baseline 
67.2  
(19.4) 
71.5  
(20.2) 
 
Change from baseline 
6.0  
(17.5) 
-1.0  
(21.5) 
Fatigue (FACIT-F)4 
Baseline 
37  
(10.8) 
36  
(10.3) 
 
Change from baseline 
2.7  
(8.4) 
2.7  
(9.3) 
Vadiraja, 2017 
n=65 
2-arm randomised control trial  
Fatigue Symptom5 
Inventory 
Baseline 
Yoga (SD) 
Post 
Yoga (SD) 
 Significant differences noted between groups  
 Better decrease in fatigue severity in Yoga 
compared to control group 
 Better decrease in fatigue frequency in Yoga 
compared to control group 
  
Fatigue severity  17.1  
(9.4) 
6.7  
(7.1) 
Fatigue frequency 
  
8.7  
(4.8) 
  
3.7  
(4.0) 
  
 
 
                                                          
2
 Standard deviation if reported in the study 
3
 Scores 0 -100. Higher score means higher response level 
4
 Higher score means better QoL 
5
 Higher score means more fatigue 
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Study Size and Design Data Mean (SD) Findings 
Headley, 2004 
n=32 
Quasi-experimental pilot study with 
randomised trial 
Combined 
(Intervention + 
Control) 
Baseline  
 
Post  Fatigue increases in women with MBC as 
chemotherapy cycles progress  
 Intervention group experienced less increase in 
fatigue and slower decrease in physical QoL vs. 
control 
 Spousal support in intervention group possible 
confounder 
   
FACIT-F   
  
  
120.6  
(22.8) 
  
  
99.6  
(29.5) 
  
  
Block, 2009 
n=90 
Consecutive case series 
Survival rate BCICT Comparable 
MBC group 
 BCICT group survival rate approximately double that 
of comparison groups 
 Substantially more favourable survival rate for MBC 
patients undergoing comprehensive or integrative 
cancer care 
 Survival of BCICT prognostic subgroups longer than 
those of the comparator populations 
 
Median survival 38 months 20 months 
3-years survival  
5-years survival 
52% 
27% 
- 
17%  
Diagnosis after 1990 32 months  15.8 months  
Carson, 2007 
n=13 
Pilot study 
Daily diary log  
(P <0.01) 
Beta score6 t-score7  Yoga practice resulted in lower pain and fatigue in 
MBC patients 
 Positive effects of Yoga practice carried over to the 
next day 
 
Fatigue (baseline 
intercept) 
46.7  11.8  
Treatment time 
  
-3.29  -1.45 
                                                          
6
 Regression analysis indicating an inverse relationship between increased Yoga practice and decreased fatigue 
7
 Used to determine if the null hypothesis is correct i.e., Yoga more effective 
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Study Size and Design Data Findings 
Yee, 2014 
n=71 
Observation study 
  MBC group 
(SD) 
Healthy 
group (SD) 
 Fatigue significantly higher in MBC group vs. healthy 
group 
 The women with MBC were significantly less active 
 MBC group spent significantly lower duration 
engaged in moderate to vigorous physical activity 
 MBC group had significantly lower estimated 
VO2max vs. healthy women 
 MBC group significantly weaker - absolute and 
relative strength measures 
FACIT-F 38.0  
(9.8) 
46.3  
(4.6) 
EORTC QLQ-30  
  
  
70.8  
(20.4) 
  
  
81.7  
(15.0) 
  
  
Born, 2010 
n=1 
Case report 
  Baseline Post  Self-report QoL – improvement in social functioning 
and vitality 
 Physical functioning, role limitation and health 
change - unchanged 
 Clinically relevant improvement in 6-minute walk 
test - exercise capacity 
 Attention patient received may be a confounder 
RAND-36 QLQ 
  
  
10  
  
  
20  
  
  
 
  
Quality of life 
Three studies investigated QoL as an outcome. Ligibel et al (2016) reported that 
participants in the intervention group (moderate exercise) reported nonsignificant 
improvements in global QoL. Headley et al (2004) reported that the intervention group 
(seated exercise) experienced a slower decrease in physical quality of life versus the control 
group with successive chemotherapy cycles. The study also reported that the women in the 
intervention group were significantly more likely to have spousal support. Born et al (2010) 
reported on an individual case study where a clinically relevant improvement in social 
functioning and vitality was indicated after an exercise intervention using combination 
aerobic and resistance training. In conclusion, the studies generally observed an 
improvement in QoL in patients who participated in a physical exercise intervention.  
 
Survival  
 Only one study investigated survival as an outcome [75]. This study was a case series 
comparing the length of survival of patients, diagnosed before 1998, at the BCICT, versus 
comparable metastatic breast cancer populations in published studies [82, 83].  The BCICT 
patients employing both conventional and complementary therapies, had significantly more 
favourable survival outcomes than their comparators. It was noted that survival was the 
longest in the most recent cohort receiving taxane therapy – post 1990, (used in breast 
metastatic cancer) compared to other cohorts. The survival time was approximately double 
or higher that of comparable populations, despite having patients with worse prognoses. 
For the BCICT, the median survival time from metastasis was 38 months, versus 20 and 23 
months for the Anderson and Clarke studies; 3-year survival was 52% and 5-year survival 
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was 27% versus 17% reported by Anderson et al (2000). The authors concluded that the 
results of the comprehensive approach to treatment by the BCICT was indicative of 
considerably more favourable survival outcomes for metastatic breast cancer patients.  
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DISCUSSION 
 This systematic review provides an overview of the available studies that have 
investigated the effects of physical exercise and nutrition interventions on body 
composition, fatigue, QoL and survival in patients with metastatic breast cancer. Our 
findings indicate that only three small RCTs in patients with metastatic breast cancer 
applying an exercise intervention have been conducted, and no studies have investigated 
the combined effects of physical exercise and nutrition, nor nutrition interventions only. The 
effect on body composition could not be evaluated as none of the studies reported on this 
outcome. This is a major gap in the literature. Moreover, the studies are very heterogenous, 
with incongruent methods of reporting, making it impossible to meta-analyse the results on 
fatigue, QoL or survival.  
Based on our findings, there is a cautious indication that exercise at least does not 
worsen fatigue, quality of life or survival and two RCTs with a minimum intervention of 
twelve weeks found a beneficial effect on fatigue. In summary, improvements in reported 
fatigue levels were noted in patients who participated in an exercise intervention, or were 
more physically active, as compared to control patients or those who were less physically 
active [78, 80].  
 
Limitations of the review and included studies 
 Given the upcoming/rising number of people living with metastatic breast cancer 
and the scarcity of physical exercise and nutrition research in advanced disease, it was 
essential to explore studies conducted in this population. The effects of the interventions in 
women undergoing active treatment for curative intent would be different to that of the 
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metastatic population, which would primarily be palliative. Therefore, the current results 
are translatable to the population of women with metastatic breast cancer, but caution 
must be exercised as the individual studies lack statistical power due to small sample sizes 
and, in one case, high attrition. Furthermore, the available studies had a considerable 
degree of heterogeneity between studies as to mode, frequency and intensity of exercise, 
treatment of control arms and method of reporting the data.  
RCTs are considered the gold standard in research as they aim to reduce overall bias 
and determine if and how a therapeutic intervention works, and whether results can be 
generalised to the population in question. Only two RCTs and one quasi-RCT qualified for 
inclusion in this review [78-80]. Of these, one was an experimental pilot study, and another 
had two intervention arms (exercise versus counseling). Another three studies did not have 
a control arm and randomization was not applicable [75-77], and the final study was an 
individual case [76]. As a result, of the diversity in structure, intervention and design, it was 
impossible to compare the studies to determine the prognostic effects or efficacy of 
interventions. 
Another limitation to the review resulted from the inclusion of studies that rely on 
patient self-report data, which are highly subjective and lead to inherent increased risk of 
bias regarding the measurement and significance of the outcome [78, 79]. One study 
reported nonsignificant results, which could have been affected by a very high attrition rate 
in the intervention arm [79]. Subjective data and high attrition rates negatively impact the 
robustness of the results from these studies. While some studies accounted for possible 
confounders, this was not the case for all. Spousal support [78] as well as attention received 
during the intervention [76] were indicated as confounding factors in two of the studies. The 
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other studies either did not account for confounding or reported intent to treat or covariate 
analysis. This compounded the fact that the studies had low statistical power due to small 
samples and further reduced the ability of the review to determine what, if any, inferences 
can be drawn from the study findings. 
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4.0 CONCLUSIONS  
Implications for Practice 
 Because of the significant advances in treatment, survivorship has increased in the 
population with metastatic disease. As the treatments are mainly palliative in nature [84], 
gaining quality of life becomes a most significant target. This study shows that physical 
exercise is safe and may improve body composition, QoL, treatment toxicity and survival in 
metastatic cancer patients, including breast cancer [84-86].  
Implications for research 
Women with metastatic disease have historically been excluded from lifestyle 
interventions as they will eventually succumb to the disease [84]. However, it is evident 
from the growing number of survivors that there are indications that physical exercise and 
nutrition interventions can improve their wellbeing and outcomes. Body composition, 
weight and muscle strength are significant prognostic factors [45, 87] and the lack of 
research in the area indicates that more studies are needed to provide best practice advice 
to these women. It is not known what dosage and type of physical exercise and nutrition 
supplementation are necessary for achieving the best possible body composition and 
maintaining it for as long as possible. For example, how often should it be done, which 
exercises are best, what mode should be used, is home-based or group exercises more 
effective than supervised exercise interventions? What is the role of telehealth in this 
space? The best nutritional management of the disease, for example, supplementation, 
protein and omega-3 fatty acids, needs to be investigated to indicate effective dosage and 
timing. 
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For future studies, further work is needed regarding conducting high-quality RCTs 
with robust study designs that encompass larger sample sizes with high statistical power. 
Studies should incorporate appropriate intervention and comparison groups to accurately 
determine the most effective parameters of physical exercise and nutrition to achieve the 
desired outcome measures. Consensus also needs to be attained regarding the most 
appropriate types of exercise and standard measures of reporting to enable meta-analysis. 
Another topic that this review has brought to light is the issue of blinding of the observers 
by using independent data analysts and longer follow-up of the participants. Most 
significantly, there were no studies that looked at body composition. Additionally, there 
were no RCTs or observational studies that included both physical exercise and nutrition 
interventions. It is not known if the combination of both these variables would increase the 
ability of these patients to manage body composition and thus achieve better quality of life 
for longer. 
These recommendations are based on ideal world considerations, however, there 
are practical, ethical and financial challenges involved in conducting studies with, for 
example, large sample sizes in this vulnerable population. Consequently, researchers could 
use the model of the Block Institute and appraise the efficacy of interventions with 
comparative groups in published studies. Alternatively, with the rise in popularity of 
telehealth, this is an avenue that could be explored to reduce burden and cost on these 
patients and possibly reduce study dropouts.  Innovative thinking is required to overcome 
the hurdles and provide practitioners with evidence-based guidance, and this growing 
population of women the best opportunity to enjoy good quality of life for the time they do 
have.  
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APPENDICES 
 
Appendix 1 
 
Common Diagnostic Tests 
X-ray Used to detect changes in the bones or chest that may be 
caused by cancer 
Bone scan A bone scan can pick up small areas in the bones where 
cells are growing more quickly. These are called ‘hot 
spots’.  
Blood tests Blood tests can be used to for several checks things, 
including liver function, how healthy the bone marrow is 
and calcium levels in the blood.  
Ultrasound This may be used to look for changes in the liver and 
elsewhere in the body 
Computed tomography  
(CT / CAT scan) 
A CT scan may be used to look for cancer in different parts 
of the body.  
Magnetic resonance imaging (MRI) An MRI scan may be used to check for signs of cancer in 
the brain, spinal cord or spine. It may also be used to look 
for cancer in the liver.  
Position emission tomography  
(PET scan) 
A PET scan may be recommended to look for metastatic 
cancer. The scan can show any areas in the body where 
cells are more active than usual (e.g. fast-growing cancer 
cells). 
Breast biopsy The breast biopsy is done to confirm the diagnosis and find 
out what receptors are on the breast cancer cells. This 
information will help doctors work out which treatments 
are best. 
 
[88] 
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Appendix 2  
 
Final Search Terms 
 
Search conducted October 25, 2017 
Pubmed 
(“Stage IV”[tiab] OR metasta*[tiab] OR “secondary”[tiab] or “Stage four”[tiab])  
AND 
(((Breast[tiab] OR Mammalia*[tiab]) AND (Malignan*[tiab] OR Neoplas*[tiab] OR Tumor*[tiab] OR 
cancer*[tiab] OR tumour*[tiab] OR carcinoma*[tiab]))  
OR "Breast Neoplasms"[Mesh]) 
AND 
((((Protein[tiab] OR “amino acid” [tiab]) AND (supplement*[tiab])) OR nutrition*[tiab] OR diet*[tiab] 
OR food[tiab] OR nutritive[tiab] OR "Fatty Acid” [tiab] OR "Fatty Acids”[tiab] OR "fatty acids, omega-
3"[MeSH] OR "Fish Oils"[Mesh] OR "Fish Oil"[tiab] OR "Fish Oils"[tiab] OR “omega 3”[tiab] OR "n-3 
fatty acid"[tiab] OR "n3 fatty acid"[tiab] OR “n3-fatty acids”[tiab] OR “n-3 fatty acids”[tiab] OR "n-3 
PUFA"[tiab] OR "n3 PUFA"[tiab] OR "n-3 polyunsaturated"[tiab] OR "n3 polyunsaturated"[tiab] OR 
"n3 poly unsaturated"[tiab] OR "n-3 poly unsaturated"[tiab] OR "seal oil"[tiab] OR "krill oil"[tiab] OR 
"cod oil"[tiab] OR Eicosapentaenoic Acid*[tiab] OR Docosahexaenoic acid*[tiab]) OR 
(“Physical activity”[tiab] OR “exercise movement techniques”[Mesh] OR “resistance training”[tiab] 
OR cardiovascular[tiab] OR exercise[tiab] OR Yoga[tiab] OR pilates[tiab] OR hydrotherapy[tiab] OR 
aerobic*[tiab] OR "Exercise Therapy”[Mesh] OR "Resistance Training"[Mesh]))  
AND  
(therapy[tiab] OR therapeutic[tiab] OR support[tiab] OR program*[tiab] OR intervention[tiab]) 
 
CINAHL 
(“Stage IV” OR metasta* OR “secondary” or “Stage four” OR MH "Neoplasm Metastasis+")  
AND 
(((Breast OR Mammalia* OR MH "Breast+") 
AND  
(Malignan* OR Neoplas* OR Tumor* OR cancer* OR tumour* OR carcinoma* OR MH "Neoplasms+") 
OR MH "Breast Neoplasms+") 
AND 
((((Protein OR “amino acid”) AND (supplement*)) OR nutrition* OR diet* OR food OR nutritive OR 
MH "Fatty Acids, Omega-3+" OR MH "Fish Oils+" OR "Fatty Acid”  OR "Fatty Acids” OR "Fish Oil" OR 
"Fish Oils" OR “omega 3” OR "n-3 fatty acid" OR "n3 fatty acid" OR “n3-fatty acids” OR “n-3 fatty 
acids” OR "n-3 PUFA" OR "n3 PUFA" OR "n-3 polyunsaturated" OR "n3 polyunsaturated" OR "n3 poly 
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unsaturated" OR "n-3 poly unsaturated" OR "seal oil" OR "krill oil" OR "cod oil" OR Eicosapentaenoic 
Acid* OR Docosahexaenoic acid*) OR 
(“Physical activity” OR MH "Exercise+" OR “resistance training” OR cardiovascular OR exercise OR 
Yoga OR pilates OR hydrotherapy OR aerobic* OR MH "Therapeutic Exercise+"))  
AND  
(therapy OR therapeutic OR support OR program* OR intervention*) 
 
EMBASE 
(“Stage IV”:ti,ab OR metasta*:ti,ab OR “secondary”:ti,ab or “Stage four”:ti,ab OR 'metastasis'/exp)   
AND 
(((Breast:ti,ab OR Mammalia*:ti,ab OR  'breast'/exp) 
AND  
(Malignan*:ti,ab OR Neoplas*:ti,ab OR Tumor*:ti,ab OR cancer*:ti,ab OR tumour*:ti,ab OR 
carcinoma*:ti,ab OR 'neoplasm'/exp)) OR 'breast cancer'/exp) 
AND 
((((Protein:ti,ab OR “amino acid”:ti,ab) AND (supplement*:ti,ab)) OR nutrition*:ti,ab OR diet*:ti,ab 
OR food:ti,ab OR nutritive:ti,ab OR 'omega 3 fatty acid'/exp OR 'fish oil'/exp OR "Fatty Acid”:ti,ab OR 
"Fatty Acids”:ti,ab OR "Fish Oil":ti,ab OR "Fish Oils":ti,ab OR “omega 3”:ti,ab OR "n-3 fatty acid":ti,ab 
OR "n3 fatty acid":ti,ab OR “n3-fatty acids”:ti,ab OR “n-3 fatty acids”:ti,ab OR "n-3 PUFA":ti,ab OR 
"n3 PUFA":ti,ab OR "n-3 polyunsaturated":ti,ab OR "n3 polyunsaturated":ti,ab OR "n3 poly 
unsaturated":ti,ab OR "n-3 poly unsaturated":ti,ab OR "seal oil":ti,ab OR "krill oil":ti,ab OR "cod 
oil":ti,ab OR “Eicosapentaenoic Acid*”:ti,ab OR “Docosahexaenoic acid*”:ti,ab) OR 
(“Physical activity”:ti,ab OR 'exercise'/exp OR “resistance training”:ti,ab OR cardiovascular:ti,ab OR 
exercise:ti,ab OR Yoga:ti,ab OR pilates:ti,ab OR hydrotherapy:ti,ab OR aerobic*:ti,ab))  
AND  
(therapy:ti,ab OR therapeutic:ti,ab OR support:ti,ab OR program*:ti,ab OR intervention*:ti,ab) 
 
Cochrane Central Database 
("Stage IV" OR metasta* OR secondary OR "Stage four")  
AND 
(((Breast OR Mammalia*) AND (Malignan* OR Neoplas* OR Tumor* OR cancer* OR tumour* OR 
carcinoma*)) OR [mh "Breast Neoplasms"]) 
AND 
((((Protein OR "amino acid") AND (supplement*)) OR nutrition* OR diet* OR food OR nutritive OR 
[mh “Fatty Acids, Omega-3”] OR [mh "fish oil"] OR "Fatty Acid”  OR "Fatty Acids” OR "Fish Oil" OR 
"Fish Oils" OR “omega 3” OR "n-3 fatty acid" OR "n3 fatty acid" OR “n3-fatty acids” OR “n-3 fatty 
acids” OR "n-3 PUFA" OR "n3 PUFA" OR "n-3 polyunsaturated" OR "n3 polyunsaturated" OR "n3 poly 
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unsaturated" OR "n-3 poly unsaturated" OR "seal oil" OR "krill oil" OR "cod oil" OR Eicosapentaenoic 
Acid* OR Docosahexaenoic acid*)  
OR 
("Physical activity" OR [mh "exercise movement techniques"] OR "resistance training" OR 
cardiovascular OR exercise OR Yoga OR pilates OR hydrotherapy OR aerobic* OR [mh "Exercise 
Therapy"] OR [mh "Resistance Training"])) AND 
(therapy OR therapeutic OR support OR program* OR intervention) 
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Appendix 3 
 
Summary Table - Stages of Breast Cancer  
Stage  Description 
Stage 0  Stage 0 is used to describe non-invasive breast cancers, such as DCIS (ductal 
carcinoma in situ). There is no evidence of cancer cells or non-cancerous 
abnormal cells breaking out of the part of the breast in which they started, or 
getting through to or invading neighboring normal tissue. 
Stage I  
(includes 
subcategories IA 
or IB) 
Stage I describes invasive breast cancer (cancer cells are breaking through to or 
invading normal surrounding breast tissue)  
Microscopic invasion is possible in stage I breast cancer. In microscopic invasion, 
the cancer cells have just started to invade the tissue outside the lining of the 
duct or lobule, but the invading cancer cells can't measure more than 1 
millimeter. 
Stage II 
(includes 
subcategories IIA 
or IIB) 
Stage IIA describes invasive breast cancer in which: 
no tumor can be found in the breast, but cancer (larger than 2 millimeters) is 
found in 1 to 3 axillary lymph nodes (the lymph nodes under the arm) or in the 
lymph nodes near the breast bone (found during a sentinel node biopsy) OR 
the tumor is larger than 2 centimeters but not larger than 5 centimeters and has 
not spread to the axillary lymph nodes 
Stage IIB describes invasive breast cancer in which: 
the tumor is larger than 2 centimeters but no larger than 5 centimeters; small 
groups of breast cancer cells -- larger than 0.2 millimeter but not larger than 2 
millimeters -- are found in the lymph nodes or lymph nodes near the breastbone 
the tumor is larger than 5 centimeters but has not spread to the axillary lymph 
nodes 
Stage III 
(includes 
subcategories 
IIIA, IIIB or IIIC) 
Stage III is divided into subcategories known as IIIA, IIIB, and IIIC. 
Stage IIIA describes invasive breast cancer in which either: 
no tumor is found in the breast or the tumor may be any size; cancer is found in 
4 to 9 axillary lymph nodes or in the lymph nodes near the breastbone (found 
during imaging tests or a physical exam) OR 
the tumor is larger than 5 centimeters; cancer has spread to 1 to 3 axillary lymph 
nodes or to the lymph nodes near the breastbone (found during a sentinel 
lymph node biopsy) 
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Stage IIIB describes invasive breast cancer in which: 
the tumor may be any size and has spread to the chest wall and/or skin of the 
breast and caused swelling or an ulcer AND 
may have spread to up to 9 axillary lymph nodes OR 
may have spread to lymph nodes near the breastbone 
Inflammatory breast cancer is considered at least stage IIIB. Typical features of 
inflammatory breast cancer and cancer cells have spread to the lymph nodes 
and may be found in the skin 
Stage IIIC describes invasive breast cancer in which: 
there may be no sign of cancer in the breast or, if there is a tumor, it may be any 
size and may have spread to the chest wall and/or the skin of the breast AND 
the cancer has spread to 10 or more axillary lymph nodes OR 
the cancer has spread to lymph nodes above or below the collarbone OR 
the cancer has spread to axillary lymph nodes or to lymph nodes near the 
breastbone 
Stage IV Stage IV describes invasive breast cancer that has spread beyond the breast and 
nearby lymph nodes to other organs of the body, such as the lungs, distant 
lymph nodes, skin, bones, liver, or brain. 
You may hear the words “advanced” and “metastatic” used to describe stage IV 
breast cancer. Cancer may be stage IV at first diagnosis or it can be a recurrence 
of a previous breast cancer that has spread to other parts of the body. 
 
[89] 
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Appendix 4  
 
Prospero Registration 
 
Van: CRD-REGISTER <irss505@york.ac.uk> 
Datum: 7 December 2017 om 00:36:10 GMT+10 
Aan: "bvanderm@bond.edu.au" <bvanderm@bond.edu.au> 
Onderwerp: PROSPERO Registration message [80412] 
Antwoord aan: crd-register irss505@york.ac.uk 
 
Dear Dr. van der Meij, 
 
Thank you for submitting details of your systematic review "Systematic review of the effects 
of physical exercise and/or nutrition interventions on women with metastatic breast cancer" 
to the PROSPERO register. We are pleased to confirm that the record will be published 
within the next hour. 
 
Your registration number is: CRD42017080412 
 
As your review progresses, please update field #28 (strategy for data synthesis) with the 
structure of your meta-analysis when this becomes established. 
 
You are free to update the record at any time, all submitted changes will be displayed as the 
latest version with previous versions available to public view. Please also give brief details of 
the key changes in the Revision notes facility. You can log in to PROSPERO and access your 
records at https://www.crd.york.ac.uk/PROSPERO 
 
Comments and feedback on your experience of registering with PROSPERO are welcome at: 
crd-register@york.ac.uk 
 
Best wishes for the successful completion of your review. 
 
Yours sincerely, 
PROSPERO Administrator 
Centre for Reviews and Dissemination 
University of York 
York YO10 5DD 
t: +44 (0) 1904 321049 
e: CRD-register@york.ac.uk 
www.york.ac.uk/inst/crd 
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Downs and Black Assessment Tool 
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Appendix 6 
 
Journal of Supportive Care in Cancer – Author Instructions 
 
TYPES OF PAPERS 
Review Articles – generally solicited by the editors but unsolicited proposals containing an 
abstract and outline can be sent to the editors for consideration. The word limit for Review 
Articles is up to 4,000 words for body text (excludes figures, charts, references, abstract). 
Methodological guidelines include 
• PRISMA or MOOSE for systematic reviews and meta-analysis 
 
TITLE PAGE 
The title page should include: 
The name(s) of the author(s) 
A concise and informative title 
The affiliation(s) and address(es) of the author(s) 
The e-mail address, and telephone number(s) of the corresponding author. If available, the 
16-digit ORCID of the author(s) 
 
Abstract 
Please provide an abstract of 150 to 250 words. The abstract should not contain any 
undefined abbreviations or unspecified references. 
Keywords 
Please provide 4 to 6 keywords which can be used for indexing purposes. 
REVIEW PROCEDURE 
All manuscripts undergo strict peer review. Manuscripts are initially considered by the 
Editor-in-Chief. Any manuscript that does not meet the general certain criteria of the 
journal, e.g. 
• relevance to the aims of the journal with the topic being of overall general interest 
• sufficiently original and contributing to the advancement of the field, 
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• clearly written with appropriate study methods, well-supported data and conclusions 
which are supported by the data will be returned to the author without review. 
MANUSCRIPT PREPARATION 
We urge authors to follow the guidelines for authors to speed up the review and publication 
process. All manuscripts are subject to copyediting upon acceptance, however, authors are 
asked to ensure that manuscripts from non-native English language speakers should have 
the language and grammar checked by a native speaker or a professional agency. Poorly 
written articles cannot be reviewed and will be returned to the authors. 
 
Authorship Criteria and Contributions 
All listed authors should have seen and approved the final version of the manuscript. All 
authors of accepted articles must sign an authorship form affirming that they have met all 
three of the following criteria for authorship, thereby accepting public responsibility for 
appropriate portions of the content: 
1. substantial contributions to conception and design, or acquisition of data, or analysis and 
interpretation of data; 
2. drafting the article or revising it critically for important intellectual content; 
3. approval of the version to be published and all subsequent versions. 
Group members who are not authors should be listed in the Acknowledgment section of the 
manuscript as participating investigators. Individuals who do not meet the criteria for 
authorship but who have made substantial, direct contributions to the work (e.g., purely 
technical help, writing assistance, general or financial or material support) should be 
acknowledged in the Acknowledgments section of the manuscript, with a brief description 
of their contributions. Authors should obtain written permission from anyone they wish to 
list in the Acknowledgments section. 
 
Redundant, Duplicate or Fraudulent Publication 
Authors must not simultaneously submit their manuscripts to another publication if that 
manuscript is under consideration by Supportive Care in Cancer. Redundant or duplicate 
publication is a paper that overlaps substantially with one already published in print or 
electronic media. At the time of manuscript submission, authors must inform the editor 
about all submissions and previous publications that might be regarded as redundant or 
duplicate publication of the same or very similar work. Any such publication must be 
referred to and referenced in the new paper. 
Copies of such material should be included with the submitted paper as a supplemental file. 
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TITLE PAGE 
Title Page 
The title page should include: 
The name(s) of the author(s) 
A concise and informative title 
The affiliation(s) and address(es) of the author(s) 
The e-mail address, and telephone number(s) of the corresponding author 
If available, the 16-digit ORCID of the author(s) 
 
Abstract 
Please provide a structured abstract of 150 to 250 words which should be divided into the 
following sections: 
Purpose (stating the main purposes and research question) 
Methods 
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